thiophenes has been researched along with pi103 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alix, S; Box, G; Chuckowree, I; Clarke, PA; De Haven Brandon, A; Di Stefano, F; Eccles, SA; Folkes, A; Gowan, S; Hayes, A; Henley, AT; Lensun, L; McDonald, E; Patel, S; Pergl-Wilson, G; Raynaud, FI; Robson, A; Saghir, N; Sheldrake, P; Shuttleworth, S; Valenti, M; Wan, NC; Workman, P; Zhyvoloup, A | 1 |
1 other study(ies) available for thiophenes and pi103
| Article | Year |
|---|---|
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Topics: Administration, Oral; Animals; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Female; Furans; Glioblastoma; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Sulfonamides; Thiophenes; TOR Serine-Threonine Kinases; Umbilical Veins; Xenograft Model Antitumor Assays | 2009 |